---
layout: post
title: "Statutory Updates to Branded Prescription Drug Fee Regulations"
date: 2026-02-04 21:02:22 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-24153
original_published: 2026-01-02 00:00:00 +0000
significance: 8.00
---

# Statutory Updates to Branded Prescription Drug Fee Regulations

**Published:** February 04, 2026 21:02 UTC
**Source:** Federal Register
**Original Published:** January 02, 2026 00:00 UTC
**Document Number:** 2025-24153

## Summary

This document proposes amendments to regulations regarding the annual fee imposed on covered entities engaged in the business of manufacturing or importing certain branded prescription drugs. In response to the replacement of the Coverage Gap Discount Program with the new Manufacturer Discount Program by the Inflation Reduction Act of 2022, the proposed regulations would make updates regarding the discounts, rebates, and other price concessions used to determine branded prescription drug sales under Medicare Part D and would update for prior statutory changes. These proposed regulations would affect persons engaged in the business of manufacturing or importing certain branded prescription drugs.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2026/01/02/2025-24153/statutory-updates-to-branded-prescription-drug-fee-regulations)
- API: https://www.federalregister.gov/api/v1/documents/2025-24153

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
